A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC) [EXTENSION OF 700195808]

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naloxegol (Primary)
Indications Constipation
Focus Adverse reactions; Registrational
Acronyms KODIAC-07
Sponsors AstraZeneca

Most Recent Events

24 Jun 2016 Results of pooled analysis of three phase III studies (KODIAC 4, KODIAC 5 and KODIAC 7) published in the Advances in Therapy
16 Sep 2014 Naloxegol was approved in the US for the treatment of opioid-induced constipation, based on data from this and other trials in the phase III KODIAC programme.
10 Apr 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight